Summary & Overview
HCPCS J0174: Lecanemab-irmb Intravenous Injection, 1 mg
HCPCS Level II code J0174 designates lecanemab-irmb, a monoclonal antibody product supplied for intravenous injection in 1 mg units. As an HCPCS Level II drug code, J0174 is the billing identifier used across outpatient infusion settings and hospital outpatient departments to record administration and drug supply. The code is nationally relevant given lecanemab's role in treating neurologic disease and the high-cost, high-utilization nature of infused biologics.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on clinical context, typical sites of service, and payer considerations for coverage and billing. The publication summarizes benchmark topics such as unit-based drug billing, common billing modifiers, and payer policy themes for infused biologics.
The report provides operational detail useful for revenue cycle, compliance, and clinical teams: what the HCPCS Level II code represents, where it is typically billed, and which major commercial and public payers are commonly involved. Data limitations are noted where source details were not supplied. The focus is national in scope and intended to inform payers, providers, and billing professionals about the billing identity and practical context of J0174.
Billing Code Overview
HCPCS Level II code J0174 represents lecanemab-irmb, for intravenous injection, 1 mg. This HCPCS Level II code is used for the drug product itself and reflects a parenteral biologic administered intravenously.
Service type: Intravenous drug administration (biologic infusion)
Typical site of service: Outpatient infusion center or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an older adult with early symptomatic Alzheimer disease presenting for scheduled intravenous disease-modifying therapy with Lecanemab-irmb dosed per weight (billing unit J0174 equals 1 mg). The patient arrives to an outpatient infusion center or hospital outpatient clinic accompanied by a caregiver. Pre-infusion workflow includes verification of diagnosis, review of current medications and anticoagulation status, baseline vital signs and neurologic exam, and documentation of informed consent. An order set includes baseline brain MRI to assess for amyloid-related imaging abnormalities (ARIA) prior to initiation and periodically during treatment. Intravenous access is obtained by an infusion nurse; the pharmacy prepares the calculated dose. During the infusion the nurse monitors for infusion reactions, neurologic changes, and blood pressure. Post-infusion observation is provided per institutional protocol (often 30–60 minutes) with event documentation. Follow-up neurology or memory clinic visits occur for ongoing cognitive assessment and to review interval MRI findings and safety labs.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (standard reporting) | Use when no special circumstances apply to the service. |